Since the first description of a characteristic chromosomal aberration in B-cell lymphomas, the t(8;14) in Burkitt lymphomas by Zech et al. in 1976 [1], significant progress has been achieved in the molecular characterization of B-cell neoplasms. These advances have been spurred by the realization that characteristic chromosomal translocations, or rearrangements, tend to occur specifically in a given type of non-Hodgkin lymphoma (NHL), consistently altering the regulation of a particular gene Although characteristic genetic changes have been detected by chromosome analyses in many subtypes of NHL (Table 1) [3••], several of which are discussed subsequently in detail, the application of conventional cytogenetics is hampered by the low mitotic index characteristic of mature B-cell neoplasms like chronic lymphocytic leukemia (CLL) or multiple myeloma, or by the low number of tumor cells found in Hodgkin disease. Nevertheless, new insights into the genetic subgrouping of these neoplasms have been gathered using molecular cytogenetic techniques like fluorescence in situ hybridization (FISH) and comparative genomic hybridization. Owing to space limitations, this review is restricted to recently identified genetic abnormalities in Hodgkin disease and B-cell NHL, although Table 1 also includes several genes shown to be important in the genesis of other B-cell neoplasms, such as CLL and multiple myeloma, for the readers' interest.
Genetic alterations in Hodgkin disease
Based on Ig hypermutation [4] and gene expression studies [5] , it is now widely accepted that with very few exceptions [6, 7] , Hodgkin disease is a B-cell lymphoma [8••] . Unfortunately, as compared to B-cell NHL, hardly any data exist concerning the genetic changes underlying the pathogenesis of this neoplasm, as the scarcity of tumor cells in Hodgkin disease tissues renders chromosomal analyses of these cells largely unsuccessful. Exciting new data on the chromosomal changes in Hodgkin dis- 
Deciphering oncogenic pathways in B-cell non-Hodgkin lymphoma through molecular characterization of recurrent translocation breakpoints
The introduction of advanced long-distance inverse polymerase chain reaction-based DNA cloning techniques [16] [17] [18] [19] has greatly facilitated the identification of new oncogenes from recurrent translocations. Use of long-distance inverse polymerase chain reaction methods has led to the identification of several new genes thought to be important in non-Hodgkin lymphomagenesis, several of which are described in the sections that follow. Here we put emphasis on the more recently identified lymphomagenic genes; the interested reader will find a number of excellent reviews describing those genes identified in earlier studies to be important in the development of NHL (Table 1) 
BCL9, MUC1, Fc␥RIIB, and other 1q21-q22 genes
Abnormalities of the long arm of chromosome 1, in particular the 1q21-q22 region, occur in approximately 10 to 15% of B-cell NHLs, are usually secondary, and are associated with a poor prognosis, especially in diffuse large cell lymphomas [26, 27] . Breakpoints located at 1q21-q22 show surprising heterogeneity and involve several target genes.
In 1998, Willis and colleagues reported the cloning of a t(1;14)(q21;q32) in a pre-B acute lymphoblastic leukemia cell line, identifying the novel BCL9 gene [28] . Increased transcript levels of BCL9, which encodes a 1394-amino acid protein of unknown function that contains several pentapeptide repeats and a potential nuclear localization signal, were detectable in the cell line. Southern hybridization and FISH analyses of a panel of 39 B-cell malignancies with 1q21 abnormalities revealed the BCL9 locus to be affected in only two cases (one mantle cell lymphoma and follicular lymphoma each), however.
Recently two independent reports described the characterization of a t(1;14)(q21;q32) in the same case of large cell lymphoma, identifying dysregulation of the MUC1 gene [29, 30] . MUC1, also called EMA (epithelial membrane antigen), is a glycoprotein that contains multiple copies of a tandemly repeated mucin-like domain. This glycoprotein was previously shown to be expressed in several lymphoid malignancies (75% of lymphocyte predominance Hodgkin disease cases, 75% of plasmacytomas, and 50% of T-cell lymphomas, including essentially all anaplastic large cell lymphomas) as a result of unknown mechanisms other than 1q21-q22 rearrangements, and was shown to be involved in the progression of solid tumors [31, 32] . The t(1;14) results in the dramatic upregulation of expression of an intact MUC1 protein; none of six other genes located in an 85-kb region immediately centromeric to the MUC1 locus (CLK2, propin, COTE1, GBA, metaxin, or thrombospondin-3) were found to be overexpressed because of the translocation [30] . Southern blot analysis of 72 B-cell NHLs containing a 1q21 rearrangement revealed MUC1 rearrangement in 4 cases (6%). In addition, increased copy number (four to six copies) of the MUC1 locus was identified in 18 (10%) of 178 B-cell NHLs [29] . More recently three body-cavity-based-lymphoma (BCBL) cell lines have been reported to contain rearrangements near the MUC1 and the physically linked MDC15 (metalloproteinaselike, disintegrin-like, and cysteine-rich protein; also known as ADAM15, for a disintegrin and metalloproteinase) gene loci, and to result in MDC15 overexpression in two of the three cell lines [33] . Thus, rearrangements at this particular 1q21 region appear to be capable of producing overexpression of either MUC1 or MDC15, both of which may contribute to the extranodal presentation of certain B-cell lymphomas because of the involvement of these proteins normally in cell-cell or cell-matrix interactions [32, 34] .
By cloning the t(1;22)(q22;q11) in three follicular lymphomas also containing t(14;18), Callanan et al. [35] showed FCGR2B, which encodes the immunoreceptor tyrosine-based inhibition motif (ITIM)-containing lowaffinity IgG Fc receptor Fc␥RIIB, to be the 1q22 target of this rearrangement. Fc␥RIIB is an inhibitory coreceptor that effects negative regulation of immune responses mediated by activating receptors such as B-cell antigen receptors [36] . High levels of the Fc␥RIIB receptor alternative splice isoform Fc␥RIIb2 were specifically overexpressed in t(1;22)-positive cases, whereas b1 isoform 
BCL6 and BCL11A/EVI9
BCL6 is a highly conserved POZ/zinc finger transcription factor gene implicated in germinal center B-cell differentiation and control of inflammation [24, 39] . Deregulation of BCL6 either by Ig gene rearrangements or rearrangements that substitute promoters of a variety of heterologous genes upstream of the BCL6 coding sequences plays a pathogenic role in B-cell NHLs, particularly diffuse large B-cell lymphomas [18, 40] . Early reports that suggested a favorable prognosis for NHLs that contained BCL6 dysregulation have not been confirmed by numerous later studies; a recently published study has suggested that the prognostic impact of BCL6 translocations might differ depending on whether the gene is fused to Ig loci or other genes, the cases with non-Ig rearrangements having a worse outcome [40] . The pathways by which BCL6 deregulation leads to lymphomagenesis are poorly understood, although recent microarray studies suggest that malignant transformation by BCL6 involves the inhibition of differentiation by downregulation of Blimp-1, which encodes a transcriptional repressor that plays a key function in the differentiation of B cells to mature plasma cells, together with enhanced proliferation caused by increased c-MYC and decreased p27/Kip1 expression [41•].
New insights into BCL6 function may come from the recent cloning of the t(2;14)(p13;q32.3), a rare but recurrent event in B-cell malignancies, which led to identification of a new zinc finger gene termed BCL11A [42] . The BCL11A gene is the human homologue of mouse Evi-9, which is deregulated in murine myeloid leukemias after proviral integration [43, 44] . The gene is highly conserved, with mouse, chicken, and Xenopus homologues, and is identical within its zinc finger motifs to another human gene (BCL11B) located on chromosome 14q32.1. As with Evi-9, three major isoforms of BCL11A exist, which differ in the number of their carboxyterminal zinc fingers. 
Mucosa-associated lymphoid tissue lymphomagenesis: what are the roles of BCL10 and API2-MLT/MALT1?
In 1999, two recurrent chromosomal changes in mucosa-associated lymphoid tissue (MALT) lymphoma were characterized at the molecular level. Three groups of investigators independently showed the t(11;18)(q21;q21) to produce a fusion of API2 (also known as cIAP2, HIAP1, or MIHC) at 11q21, which encodes an inhibitor of apoptosis protein (IAP), to a gene at 18q21 named MLT or MALT1 (for MALT lymphomaassociated translocation) [ [54] .
The other recurrent translocation found in MALT lymphomas is the t(1;14)(p22;q32) [55] , which is considerably less frequent and is also thought to be associated with a more aggressive tumor biology, including H. pylori-independent growth of gastric MALT lymphomas. Willis et al. [56] and Zhang et al. [57] independently characterized t(1;14), identifying an apoptosismodulating gene, BCL10, as the 1p22 target. Intriguingly, like the API2 gene altered in the t(11;18), BCL10 encodes a caspase recruitment domain (CARD)-containing protein. CARD proteins are known to be essential for transducing either death or survival signals [58] , and initial functional studies provided evidence for a proapoptotic and NF-B-activating function of BCL10 [56, 57, [59] [60] [61] [62] [63] .
Given the data showing BCL10 to be proapoptotic in most cell types (although stable BCL10 expression could be achieved in lymphoid cell lines without inducing an apparent propensity to apoptotic death), overexpression of the gene because of t(1;14) appeared paradoxical. To address this issue, BCL10 transcripts from t(1;14)-positive MALT lymphomas [56, 57] , as well as other NHLs and solid tumors lacking the translocation [56] , were characterized and reported to contain a variety of mutations, suggesting that loss-of-function, or overexpression of gain-of-function, mutant BCL10 proteins might contribute to tumorigenesis rather than overexpression of the normal protein. These reports prompted a number of investigators to examine various tumor types for mutations in BCL10 [64] [65] [66] [67] [68] [69] [70] . Based on these studies, BCL10 mutations appear to occur very rarely in nonlymphoid hematopoietic malignancies and solid tumors of all types and are therefore unlikely to play a significant role in oncogenesis. The combined data suggest that at most 5 to 10% of B-cell NHLs may contain mutations, whereas mutation in T-lineage disease is rare. Interestingly, most mutations reported so far have been detected only in cloned cDNA fragments, and RNA editing has been suggested as a mechanism for this hitherto unknown pattern of mutations [71] . Thus, the initially reported high frequency of BCL10 mutation in a variety of hematopoietic and solid tumors [56] has not been borne out by additional data from a large number of studies. Nonetheless, BCL10 mutation may play a role in the development of a small subset of lymphoid and possibly other malignancies. However, the relative contributions of BCL10 mutants to MALT lymphomas and other tumors are not currently clear and await further study, although a classic tumor suppressor model can be regarded as unlikely. The situation is even more complicated by the fact that MALT lymphomas with either the t(1;14) or the t(11;18) display an aberrant nuclear localization of BCL10 protein by immunohistochemistry, the significance of which is not clear [72, 73] .
Functional evidence regarding the importance of BCL10 in lymphocyte development and MALT lymphomagenesis has come from recently described mouse models. Transgenic mice in which BCL10 is linked to an immunoglobulin enhancer construct that directs expression only to T and B cells develop splenomegaly because of a dramatic and specific expansion of marginal zone B cells reminiscent of human splenic marginal zone lymphoma [74] . Interestingly, these studies also revealed that mice overexpressing BCL10 mutants in their lymphocytes have no apparent abnormalities of lymphoid development or function, suggesting that deregulated expression of the normal protein by the t(1;14) rather than BCL10 mutants contributes to MALT tumorigenesis. Moreover, studies from Bcl10-deficient mice indicate that in addition to being involved in neural tube closure, Bcl10 functions as a positive regulator of lymphocyte proliferation that specifically connects antigen receptor (B-and T-cell antigen receptors) signaling in B and T cells to NF-B activation [ 
Gene expression profiling in B-cell lymphoma
Genomic scale gene expression profiling using cDNA microarrays is a promising new approach to gain deeper insights into cancer pathobiology and the mechanisms underlying treatment resistance and susceptibility. In Bcell malignancies, a recent study [ Interestingly, these microarray data also revealed considerable variation in gene expression between samples within one diagnostic category. This finding was especially true in DLBCL, in which the structure of the hierarchical clustering dendrogram indicated an inhomogeneous gene expression pattern. It has long been accepted that lymphomas classified as DLBCL might include more than one disease entity, because DLBCLs display a heterogeneous morphology and a highly variable clinical course. Based on gene expression profiling, two molecularly distinct subtypes of DLBCL could be defined (Fig. 1) : The "germinal center B-like" DLBCL expressed genes are characteristic of germinal center B cells (eg, CD10, CD38, JAW1, and A-myb), whereas the "activated B-like" DLBCL were characterized by the expression of genes that are normally induced during in vitro activation of peripheral blood B cells (eg, BCL2, cyclin D2, and IRF4). Moreover, the molecularly different subtypes of DLBCL also defined prognostic categories: 76% of germinal center B-like DLBCL patients were alive after 5 years, in contrast to only 16% of the patients with activated B-like DLBCL. Although the clinical relevance of this proposed classification scheme has to be confirmed in a larger cohort of patients, further support for the existence of at least two biologically distinct subtypes of DLBCL comes from a recent study by Lossos et al. [82] . In this study, seven DLBCL that were previously classified as germinal center B-like DLBCL [81••] were shown to have ongoing somatic mutations of the immunoglobulin (Ig) heavy chain gene. Thus, the transforming event of this subtype of DLBCL may occur while the B cell is in the germinal center microenvironment and does not significantly alter the gene expression program characteristic of this stage of B-cell differentiation, including the ability to mutate Ig genes. In contrast, five of seven tumor samples from the activated B-like DLBCL group did not show evidence of ongoing mutations and, in the remaining two cases, single point mutations were detected in only 4 of 36 molecular clones examined. Accordingly, the tumorigenic event in the activated B-like DLBCL might take place in a postgerminal center B cell or, alternatively, it could occur in a germinal center B cell, where it dramatically alters the gene expression profile and shuts off the Ig mutational machinery. These initial studies suggest that the determination of detailed molecular pictures of gene expression in B-cell malignancies might be helpful in improving current classification schemes by defining biologically and clinically more homogeneous populations of patients. Gene expression profiling should also be useful in the identification of pathogenetically relevant pathways in malignant B cells, permitting the development of alternative therapeutic strategies targeted at these pathways.
Conclusions
Dramatic progress has been made in our understanding of B-cell lymphomagenesis through the characterization of recurrent chromosomal translocations. However, despite identification of many critical oncogenes, their functional consequences and exact mechanisms of lymphoid cell transformation remain to be fully elucidated. In the future, focus will shift toward these functional questions and to the use of microarray analysis to obtain a more global insight into gene dysregulation in lymphomagenesis. 
